Biomea Fusion, Inc. filed a current report on September 22, 2026, disclosing an updated timeline for topline data from its ongoing Phase I clinical trial evaluating BMF-650 in obese, otherwise healthy volunteers.

Key Highlights

  • Updated timeline: Topline results from the Phase I GLP-131 trial for BMF-650 are now expected in October 2026.
  • Trial population: The Phase I study is enrolling obese, otherwise healthy volunteers.
  • Candidate: BMF-650 is the investigational compound under evaluation in this trial.
  • Emerging growth company: Biomea Fusion, Inc. is designated an emerging growth company as defined under applicable securities rules.
  • Signed by: Michael J.M. Hitchcock, Interim Chief Executive Officer and Director, signed the filing as Principal Executive Officer.

Biomea Fusion Shifts BMF-650 Phase I Data Window to October 2026

According to the filing, Biomea Fusion, Inc. (NASDAQ:BMEA), a Delaware-incorporated biopharmaceutical company headquartered at 1599 Industrial Road, San Carlos, California, disclosed on September 22, 2026, that it has updated the anticipated timing for topline results from its Phase I GLP-131 trial. The company reported that these results, which had been previously expected on a different schedule, are now anticipated to arrive in October 2026.

The filing identifies BMF-650 as the investigational asset at the center of this study, with the trial currently enrolling obese, otherwise healthy volunteers. The company disclosed the timing update under Item 8.01 (Other Events) of its current report, indicating that the change pertains specifically to when topline data from the ongoing Phase I program will become available. Biomea Fusion is listed on the Nasdaq Global Select Market under the trading symbol BMEA, with common stock carrying a par value of $0.0001 per share.

The filing was signed by Michael J.M. Hitchcock in his capacity as Interim Chief Executive Officer, Director, and Principal Executive Officer. The company also confirmed its status as an emerging growth company under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, and indicated that it has not elected to use the extended transition period for complying with new or revised financial accounting standards.

What Was Disclosed

Biomea Fusion disclosed a revised timeline for topline results from its Phase I GLP-131 trial evaluating BMF-650 in obese, otherwise healthy volunteers, with data now expected in October 2026, as reported under Item 8.01 of the current filing.